BOSTON | August 27, 2026 – Researchers at the Center for Regenerative Medicine (CReM) at Boston Medical Center (BMC) and Boston University (BU) have developed a scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs), overcoming a longstanding challenge in the development of stem cell-based immunotherapies. The findings, published in Stem Cell Reports, could help advance efforts to create off-the-shelf CAR-T cell therapies that can be produced at scale and made more readily available to patients.
CAR-T cell therapy works by isolating a patient's T cells, genetically modifying them to recognize and target cancer cells, and returning them to the patient. While the approach has transformed treatment for some blood cancers, producing a personalized therapy for each patient can be costly and time-intensive. IPSCs, which are generated from donated adult skin or blood cells, could enable the large-scale production of T cells that could be used "off the shelf" for many patients rather than being made individually for each one. A key challenge, however, has been reliably generating functional CD4+ helper T cells, which play an important role in coordinating and regulating immune responses.
A team of researchers led by Gustavo Mostoslavsky, M.D., Ph.D., co-director of the CReM and professor of medicine and virology, immunology and microbiology at BU Chobanian & Avedisian School of Medicine, and doctoral student Julian Amirault found the key to producing CD4+ cells is in a molecular signaling pathway called Notch. While Notch signaling is critical to early T cell development, the researchers found that removing it during later stages of maturation, while simultaneously reducing anti-T cell receptor signaling, allowed developing cells to survive and mature into CD4+ T cells at scale
"Our protocol is simple, straightforward, and potentially scalable for treatment," Dr. Mostoslavsky said. "And our system is making T cells that look like those from blood, with a full repertoire of the different subtypes."
Beyond the clinical implications, the work has also shed new light on T cell biology, revealing how Notch signaling shifts over time to direct cells toward either the CD8 or the CD4 lineage. With a workable protocol in hand, the team's next step is to introduce the chimeric antigen receptor (CAR) directly into their iPSC-derived CD4+ and CD8+ cells and test their ability to kill cancer in animal models, an important next step toward the potential development of universal CAR-T therapies.
"What we have developed represents a major advance in how the future of CAR-T could be done," said Dr. Mostoslavsky. "The potential is that one day, these cells could be ready and waiting when a patient is diagnosed. No cell collection, no individualized manufacturing, just treatment."
About Boston Medical Center Health System
Boston Medical Center Health System is an integrated academic healthcare system that models a new kind of excellence in healthcare where clinical and operational innovation meets health equity and access. BMC Health System is dedicated to advancing scientific discovery and access to care, partnering with our communities, and developing scalable approaches to restore and maintain health. With more than 15,000 dedicated employees, BMC Health System includes its founding academic medical center, Boston Medical Center, two hospitals in the community, WellSense Health Plan, and other health-enhancing entities serving patients and health plan members across New England and beyond.